| Title |
Current perspectives on the immunopathogenesis of systemic sclerosis
|
|---|---|
| Published in |
ImmunoTargets and Therapy, April 2016
|
| DOI | 10.2147/itt.s82037 |
| Pubmed ID | |
| Authors |
Patrizia Fuschiotti |
| Abstract |
Systemic sclerosis (SSc or scleroderma) is a progressive and highly debilitating autoimmune disorder characterized by inflammation, vasculopathy, and extensive fibrosis. SSc is highly heterogeneous in its clinical presentation, extent and severity of skin and internal organ involvement, and clinical course and has the highest fatality rate among connective tissue diseases. While clinical outcomes have improved in recent years, no current therapy is able to reverse or slow the natural progression of SSc, a reflection of its complex pathogenesis. Although activation of the immune system has long been recognized, the mechanisms responsible for the initiation of autoimmunity and the role of immune effector pathways in the pathogenesis of SSc remain incompletely understood. This review summarizes recent progress in disease pathogenesis with particular focus on the immunopathogenetic mechanisms of SSc. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 4 | 67% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 13% |
| Student > Ph. D. Student | 13 | 11% |
| Researcher | 13 | 11% |
| Other | 10 | 9% |
| Student > Master | 9 | 8% |
| Other | 23 | 20% |
| Unknown | 33 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 36% |
| Immunology and Microbiology | 11 | 9% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Agricultural and Biological Sciences | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 10 | 9% |
| Unknown | 37 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2020.
All research outputs
#5,243,566
of 25,748,735 outputs
Outputs from ImmunoTargets and Therapy
#1
of 1 outputs
Outputs of similar age
#76,200
of 315,638 outputs
Outputs of similar age from ImmunoTargets and Therapy
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,638 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them